18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.

@article{Cheng201318FfluoromisonidazolePA,
  title={18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.},
  author={Jingyi Cheng and Li Lei and Junyan Xu and Yifei Sun and Yongping Zhang and Xincun Wang and Lingling Pan and Graham A Colditz and Yingjian Zhang and Guangyu Liu},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2013},
  volume={54 3},
  pages={333-40}
}
UNLABELLED Although endocrine therapy is an effective method to treat estrogen receptor (ER)-positive breast cancer, approximately 30%-40% of all hormone receptor-positive tumors display de novo resistance. The aim of our current study was to analyze whether (18)F-labeled fluoromisonidazole (1-(2-nitro-1-imidazolyl)-2-hydroxy-3-fluoropropane [(18)F-FMISO]) PET/CT could predict primary resistance to hormonal therapy in ER-positive breast cancer. METHODS Postmenopausal women who had ER… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…